Core Viewpoint - The company has signed a contract with Boji Pharmaceutical Technology Co., Ltd. to assist in the clinical research and registration of a new traditional Chinese medicine product, Compound Cypra, aiming to complete clinical trials and market launch [1] Group 1 - The company is engaged in the development of traditional Chinese medicine [1] - The collaboration with Boji Pharmaceutical is expected to enhance the company's capabilities in clinical research [1] - The focus is on the clinical trial and registration process for a Class 1 new drug [1]

Core Viewpoint - The collaboration between Xiao Fang Pharmaceutical and Boji Pharmaceutical marks a significant step in the development of innovative drugs, particularly in the clinical research and registration of a new traditional Chinese medicine product [1] Group 1: Partnership Details - Xiao Fang Pharmaceutical has signed a "Technical Entrustment (Development) Contract" with Boji Pharmaceutical to assist in the clinical research and registration of a Class 1 traditional Chinese medicine compound [1] - This partnership is based on a shared strategic development vision, indicating a strong alliance between the two companies [1] Group 2: Strategic Implications - The collaboration is expected to leverage Boji Pharmaceutical's strengths in research and development, technical expertise, and clinical resources, enhancing the efficiency and success rate of the product's development [1] - The partnership aims to establish a solid foundation for the subsequent application and market launch of the product [1]

Core Viewpoint - The company, Xiao Fang Pharmaceutical, has signed a technical entrustment contract with Boji Pharmaceutical to assist in the clinical research and registration of a new traditional Chinese medicine, Compound Cypraea Tincture, which is classified as a Class 1 new drug [1] Group 1 - The collaboration aims to facilitate the completion of clinical trials and the subsequent market launch of the new drug [1] - This transaction does not constitute a major asset restructuring or a related party transaction [1] - The agreement is not expected to have a significant impact on the company's operating results for the current fiscal year [1]

Core Viewpoint - The collaboration between the company and Boji Pharmaceutical Technology Co., Ltd. marks a significant step in the company's strategic development in the innovative drug sector, focusing on the clinical research and registration of a new traditional Chinese medicine product [1] Group 1: Partnership Details - The company has signed a "Technical Entrustment (Development) Contract" with Boji Pharmaceutical, which will assist in completing the clinical research and registration of a Class 1 compound medicine [1] - This partnership is described as a strong alliance based on a shared development strategy, leveraging the strengths of both parties [1] Group 2: Advantages of Collaboration - Boji Pharmaceutical is recognized as an industry leader with significant advantages in research and development capabilities, technical accumulation, and clinical resources [1] - The collaboration is expected to create a synergistic effect, enhancing the research and development efficiency and success rate of the contracted product [1] - This partnership aims to lay a solid foundation for the subsequent application and market launch of the product [1]

Core Viewpoint - On September 25, Xiaofang Pharmaceutical experienced a decline of 5.1%, with a stock price of 33.68 CNY per share, a trading volume of 152 million CNY, a turnover rate of 8.09%, and a total market capitalization of 5.408 billion CNY [1]. Company Overview - Xiaofang Pharmaceutical Co., Ltd. is located at 777 Hongzhu Road, Fengxian District, Shanghai, and was established on August 12, 1993. The company went public on August 26, 2024. Its main business involves the research, production, and sales of external-use medications [1]. - The revenue composition of Xiaofang Pharmaceutical is as follows: digestive medications account for 51.05%, skin medications for 39.79%, ear, nose, and throat medications for 9.08%, and other supplementary products for 0.07% [1]. Shareholder Information - Among the top ten circulating shareholders of Xiaofang Pharmaceutical, one fund under Taixin Fund ranks as a significant shareholder. The Taixin Leading Strategy Mixed Fund (290002) held 256,800 shares in the second quarter, unchanged from the previous period, representing 0.64% of the circulating shares. The estimated floating loss today is approximately 464,800 CNY [2]. - The Taixin Leading Strategy Mixed Fund (290002) was established on June 28, 2004, with a current scale of 417 million CNY. Year-to-date returns are 21.85%, ranking 4285 out of 8173 in its category; the one-year return is 34.99%, ranking 4373 out of 8003; and since inception, the return is 172.88% [2]. - The fund manager of Taixin Leading Strategy Mixed Fund is Wang Boqiang, who has a cumulative tenure of 10 years and 196 days. The total asset scale under his management is 825 million CNY, with the best fund return during his tenure being 112.25% and the worst being -36.68% [2].

Core Insights - On September 10, Xiaofang Pharmaceutical experienced a decline of 2.44% with a trading volume of 124 million yuan [1] - The company reported a financing buy-in amount of 12.38 million yuan and a financing repayment of 14.91 million yuan, resulting in a net financing buy of -2.54 million yuan [1] - As of September 10, the total financing and securities lending balance for Xiaofang Pharmaceutical was 137 million yuan, which is 7.20% of its circulating market value, indicating a high level of financing [1] Financing Overview - On September 10, Xiaofang Pharmaceutical had a financing buy-in of 12.38 million yuan, with a current financing balance of 137 million yuan, exceeding the 90th percentile level over the past year [1] - In terms of securities lending, there were no shares repaid or sold on September 10, with a total securities lending balance of 0.00 yuan, also exceeding the 90th percentile level over the past year [1] Company Performance - As of June 30, the number of shareholders for Xiaofang Pharmaceutical was 14,800, a decrease of 22.41% from the previous period, while the average circulating shares per person increased by 28.88% to 2,703 shares [2] - For the first half of 2025, Xiaofang Pharmaceutical achieved a revenue of 270 million yuan, representing a year-on-year growth of 3.06%, and a net profit attributable to shareholders of 121 million yuan, with a year-on-year increase of 1.69% [2] Dividend and Shareholding Structure - Since its A-share listing, Xiaofang Pharmaceutical has distributed a total of 241 million yuan in dividends [3] - As of June 30, 2025, among the top ten circulating shareholders, CITIC Jiantou Rotation Mixed A (003822) ranked as the third-largest shareholder with 439,400 shares, while CITIC Jiantou Selected Mixed A (008347) was the fourth-largest with 298,100 shares, both being new shareholders [3]

Core Viewpoint - The company Xiaofang Pharmaceutical has shown stable financial performance with a slight increase in revenue and net profit, while also experiencing significant activity in its financing and stockholder structure [1][2][3]. Financing and Stock Performance - On September 8, Xiaofang Pharmaceutical's stock rose by 0.37% with a trading volume of 85.47 million yuan, and the net financing purchase amounted to 3.43 million yuan [1]. - The total financing and securities balance reached 127 million yuan, accounting for 6.73% of the circulating market value, indicating a high level of financing activity [1]. - The company had no short-selling activity on September 8, with a short-selling balance of 0, reflecting a lack of bearish sentiment [1]. Financial Performance - For the first half of 2025, Xiaofang Pharmaceutical reported a revenue of 270 million yuan, representing a year-on-year growth of 3.06%, and a net profit attributable to shareholders of 121 million yuan, up by 1.69% [2]. - Cumulative cash dividends since the company's A-share listing have reached 241 million yuan [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 22.41% to 14,800, while the average circulating shares per person increased by 28.88% to 2,703 shares [2]. - Notable institutional investors include CITIC Jiantou Rotation Mixed A and CITIC Jiantou Selection Mixed A, both of which are new major shareholders [3].

Core Viewpoint - The company, Shanghai Xiaofang Pharmaceutical Co., Ltd., is set to hold an investor briefing on September 12, 2025, to discuss its 2025 semi-annual performance and financial results, allowing for interactive communication with investors [2][3][4]. Group 1: Meeting Details - The investor briefing will take place on September 12, 2025, from 11:00 AM to 12:00 PM [5][6]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online interactive format [2][4]. - Investors can submit questions from September 5 to September 11, 2025, through the Roadshow Center website or via the company's email [4][6]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [5][6]. - The company will address commonly asked questions during the briefing, ensuring transparency and engagement with the investor community [3][4].

Group 1 - The company, Xiaofang Pharmaceutical (603207), announced that it will hold a half-year performance briefing on September 12, 2025 [1]

Core Points - The company will hold a half-year performance briefing on September 12, 2025, from 11:00 to 12:00 [1] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [1] - Investors can submit questions from September 5 to September 11, 2025, via the company's email or the Roadshow Center's website [1] Meeting Details - The meeting is scheduled for September 12, 2025, from 11:00 to 12:00 [1] - Location: Shanghai Stock Exchange Roadshow Center [1] - Format: Online interactive session [1] Participants - Key attendees include the Chairman and General Manager Fang Zhiguang, Secretary of the Board and Financial Officer Luo Xiaoxu, and Independent Director Yu Wei [1] Investor Participation - Investors can join the meeting online on September 12, 2025, and will have the opportunity to ask questions [1] - Questions can be submitted in advance through the Roadshow Center's website or via the company's email [1] Contact Information - Contact person: Jiang Lili, Phone: 021-50818259, Email: info@xf-pharma.com [1] Additional Information - After the briefing, investors can access the meeting details and main content through the Shanghai Stock Exchange Roadshow Center [1]